AbbVie (NYSE:ABBV – Get Free Report) announced its earnings results on Thursday. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.08, Briefing.com reports. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.02 billion. AbbVie had a net margin of 11.02% and a return on equity of 179.47%. AbbVie’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the firm posted $2.91 earnings per share. AbbVie updated its FY24 guidance to $10.71-10.91 EPS.
AbbVie Stock Up 1.7 %
Shares of ABBV traded up $3.07 during trading hours on Friday, hitting $185.24. The company had a trading volume of 6,948,346 shares, compared to its average volume of 5,572,868. The firm has a fifty day moving average price of $167.68 and a 200-day moving average price of $169.55. The company has a debt-to-equity ratio of 7.93, a quick ratio of 0.83 and a current ratio of 0.94. The stock has a market capitalization of $327.11 billion, a price-to-earnings ratio of 54.97, a P/E/G ratio of 2.23 and a beta of 0.64. AbbVie has a 52-week low of $135.85 and a 52-week high of $186.85.
AbbVie Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Monday, July 15th will be given a $1.55 dividend. This represents a $6.20 annualized dividend and a dividend yield of 3.35%. The ex-dividend date is Monday, July 15th. AbbVie’s dividend payout ratio is presently 183.98%.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on ABBV
Insider Transactions at AbbVie
In other news, Chairman Richard A. Gonzalez sold 282,845 shares of AbbVie stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total value of $49,497,875.00. Following the completion of the transaction, the chairman now owns 513,099 shares of the company’s stock, valued at approximately $89,792,325. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.25% of the stock is owned by insiders.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also
- Five stocks we like better than AbbVie
- Consumer Staples Stocks, Explained
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Most Effectively Use the MarketBeat Earnings Screener
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Why is the Ex-Dividend Date Significant to Investors?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.